Free Trial
NYSE:EHAB

Enhabit (EHAB) Stock Price, News & Analysis

Enhabit logo
$7.98 +0.02 (+0.19%)
As of 01/17/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Enhabit Stock (NYSE:EHAB)

Key Stats

Today's Range
$7.84
$8.09
50-Day Range
$7.14
$8.75
52-Week Range
$6.85
$11.74
Volume
217,365 shs
Average Volume
250,018 shs
Market Capitalization
$401.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.75
Consensus Rating
Hold

Company Overview

Enhabit, Inc. is a leading healthcare provider that offers Medicare-certified skilled home health and hospice services in the United States. The company operates in two segments: Home Health and Hospice, providing services to adult patients needing care, including skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Enhabit's hospice services include in-home services to terminally ill patients and their families to address patients' physical needs, including pain control and symptom management, and emotional and spiritual support.

Enhabit operates home health agencies in approximately 34 states, with a concentration in the southern half of the United States. As of March 31, 2022, Enhabit operates in 252 home health agencies and 99 hospice agencies across 34 states. Enhabit provides practices to treat chronic diseases and conditions, including diabetes, arthritis, hypertension,  Alzheimer's disease, spinal stenosis, low vision,  Parkinson's disease, complex wound care, osteoporosis, and chronic pain, along with disease-specific plans for patients with diabetes, post-orthopedic surgery or injury, congestive heart failure,  and respiratory diseases.

Enhabit started as HealthSouth, founded in 1984 by Beam Scrushy and Richard Scrushy. In the early 2000s, the company restructured and rebranded into Encompass Health after being caught up in an accounting scandal. In Q2 of 2022, Enhabit, the healthcare and hospice division, became an independent public company, having completed its spinoff from Encompass Health Corporation. 

Barb Jacobsmeyer was named President and CEO of Enhabit Home Health & Hospice in June 2021. Jacobsmeyer came to Enhabit from Encompass Health, where she served as the company's executive vice president of operations. 

In Q3 of 2022, Enhabit, Inc. announced the acquisition of Caring Hearts Hospice, a locally-owned hospice agency in Texas. The acquisition adds four hospice locations in Texas to Enhabit's existing presence in the state. Ehnabit continues to expand, setting aside approximately one hundred million dollars to fund future mergers and acquisitions. 

Enhabit, Inc. is committed to providing high-quality care and service to patients and their families, and its success is a testament to its dedicated team of healthcare professionals. Enhabit is well-positioned to meet the growing demand for healthcare services in the United States as a leading home health and hospice service provider. With its focus on patient care and commitment to excellence, Enhabit is poised to continue to grow and succeed in the years ahead.

Enhabit's commitment to quality care has not gone unnoticed, as they have received numerous awards and recognitions for their services. In 2021, they were named a HomeCare Elite Top Agency for the 15th year. This recognition is given to the top-performing home health agencies in the United States. They have also received a 5-star rating from the Centers for Medicare & Medicaid Services (CMS) for their home health services, indicating their high quality and patient satisfaction.

Enhabit's success can be attributed to its skilled and compassionate staff and dedication to providing comprehensive and individualized patient care. Enhabit also recognizes the importance of emotional and spiritual support for their patients and their families, particularly in hospice care. Their hospice services include pain and symptom management, spiritual counseling, palliative and dietary counseling, social worker visits, and bereavement counseling services to meet terminally ill patients and their families' individual physical, spiritual, emotional, and psychosocial needs.

Enhabit Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
46th Percentile Overall Score

EHAB MarketRank™: 

Enhabit scored higher than 46% of companies evaluated by MarketBeat, and ranked 681st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Enhabit has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Enhabit has only been the subject of 2 research reports in the past 90 days.

  • Read more about Enhabit's stock forecast and price target.
  • Earnings Growth

    Earnings for Enhabit are expected to grow by 27.27% in the coming year, from $0.22 to $0.28 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Enhabit is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Enhabit is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Enhabit has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Enhabit's valuation and earnings.
  • Percentage of Shares Shorted

    2.78% of the float of Enhabit has been sold short.
  • Short Interest Ratio / Days to Cover

    Enhabit has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enhabit has recently decreased by 5.43%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Enhabit does not currently pay a dividend.

  • Dividend Growth

    Enhabit does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.78% of the float of Enhabit has been sold short.
  • Short Interest Ratio / Days to Cover

    Enhabit has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enhabit has recently decreased by 5.43%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Enhabit has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Enhabit this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Enhabit insiders have bought more of their company's stock than they have sold. Specifically, they have bought $166,910.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 1.90% of the stock of Enhabit is held by insiders.

  • Read more about Enhabit's insider trading history.
Receive EHAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enhabit and its competitors with MarketBeat's FREE daily newsletter.

EHAB Stock News Headlines

Must-See: 5-Second Trump Prediction
President Trump's prediction is about to become a reality... Opening a rare window of opportunity for you to accelerate your retirement during the first 100 days of his administration.
Jefferies Upgrades Enhabit (EHAB)
See More Headlines

EHAB Stock Analysis - Frequently Asked Questions

Enhabit's stock was trading at $7.81 on January 1st, 2025. Since then, EHAB stock has increased by 2.2% and is now trading at $7.9850.
View the best growth stocks for 2025 here
.

Enhabit, Inc. (NYSE:EHAB) released its earnings results on Wednesday, November, 6th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by $0.01. The company had revenue of $253.60 million for the quarter, compared to analyst estimates of $261.69 million. Enhabit had a positive trailing twelve-month return on equity of 1.67% and a negative net margin of 11.24%.

Shares of EHAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enhabit investors own include Alphabet (GOOG), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX), Home Depot (HD) and Meta Platforms (META).

Company Calendar

Last Earnings
11/06/2024
Today
1/20/2025
Next Earnings (Estimated)
3/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Home health care services
Sub-Industry
Healthcare
Fax
N/A
Employees
10,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.75
High Stock Price Target
$9.50
Low Stock Price Target
$8.00
Potential Upside/Downside
+9.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Net Income
$-80,500,000.00
Pretax Margin
-11.00%

Debt

Sales & Book Value

Annual Sales
$1.05 billion
Cash Flow
$2.73 per share
Book Value
$13.90 per share

Miscellaneous

Free Float
49,329,000
Market Cap
$401.49 million
Optionable
Optionable
Beta
1.82
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NYSE:EHAB) was last updated on 1/20/2025 by MarketBeat.com Staff
From Our Partners